Litcius/Paper detail

Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial

Anca Askanase, David D’Cruz, Kenneth Kalunian, Joan T. Merrill, Sandra V Navarra, Clélia Cahuzac, Peter Cornelisse, Mark Murphy, Daniel S. Strasser, L. Trokan, Ouali Berkani

2024The Lancet Rheumatology16 citationsDOI

Topics & Concepts

PlaceboDouble blindSphingosine-1-phosphate receptorMedicineInternal medicineSphingosine-1-phosphateSphingosinePharmacologyReceptorAlternative medicinePathologySystemic Lupus Erythematosus ResearchSphingolipid Metabolism and SignalingSpondyloarthritis Studies and Treatments
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial | Litcius